1 / 16

Contrast-Enhanced Neuro MRA in the NSF Era: Possible Contrast Dose Reduction with a High- Relaxivity Contrast Agent

Contrast-Enhanced Neuro MRA in the NSF Era: Possible Contrast Dose Reduction with a High- Relaxivity Contrast Agent. Matthew J. Kuhn, MD Department of Radiology University of Illinois School of Medicine Peoria, IL, USA mkuhn6@gmail.com. Background.

gratiana
Download Presentation

Contrast-Enhanced Neuro MRA in the NSF Era: Possible Contrast Dose Reduction with a High- Relaxivity Contrast Agent

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Contrast-Enhanced Neuro MRA in the NSF Era: Possible Contrast Dose Reduction with a High- Relaxivity Contrast Agent Matthew J. Kuhn, MD Department of Radiology University of Illinois School of Medicine Peoria, IL, USA mkuhn6@gmail.com

  2. Background • Higher doses of gadolinium-based contrast agents (GBCA) are often used for contrast-enhanced MRA (CE-MRA) • Patients with moderate-to-severe (stages 3-5) chronic kidney disease undergoing contrast-enhanced MR imaging are known to be at increased risk for developing nephrogenic systemic fibrosis (NSF) • Risk increases with higher GBCM doses or repeated GBCM exposures (1-2) • Herein we review information on the application of lower doses of the higher-relaxivity gadobenate dimeglumine (MultiHance; Gd-BOPTA) for CE-MRA of the carotid arteries and intracranial vessels

  3. r1 and r2 Relaxivities at Different Magnet Strengths* *Measured in human plasma at 37°C Pintaske J. Invest Radiol 2006;41:213-221 (3)

  4. Abdominal Aorta MRA Crossover Comparison Higher peak/shorter T1 30 Gd-DTPA Gd-BOPTA Wider plateau Equivalent 0.1mmol/kg doses at 2 mL/s 25 Higher tail Mean Signal Intensity (a.u.) 20 15 AA AAAA 40 60 80 100 120 140 Time (s) Knopp MV. Invest Radiol 2002;37:706-715 (4)

  5. Methods and Materials • 2 intraindividual crossover studies (5-6) • Total of 24 patients underwent CE-MRA with • Higher-relaxivity agent gadobenate dimeglumine (Gd-BOPTA), and • Conventional contrast agent gadopentetate dimeglumine (Gd-DTPA) for CE-MRA • All subjects received both agents in 2 separate but identical imaging studies • Contrast enhancement evaluated in a blinded manner using both qualitative and quantitative metrics

  6. Study 1: Comparison of Equal Doses of Gd-BOPTA and Gd-DTPA • 12 healthy subjects evaluated with equal 0.1 mmol/kg bodyweight doses of Gd-DTPA and Gd-BOPTA • Significant (p≤0.021) ↑ in CNR with Gd-BOPTA; overall increases of • 23.3% - internal carotid • 26.7% - middle cerebral • 28.5% - basilar arteries • Significant (p≤0.026) reader preference for Gd-BOPTA globally and for assessments of extracranial arteries, Circle of Willis, and vessels distal to Circle of Willis Bueltmann E. Invest Radiol 2008; 43:695–702

  7. CNR in the ICA, MCA, and BA

  8. Preferences Following Matched-Pairs Comparison of Image Sets

  9. Supra-Aortic MRA Crossover Comparison 0.1 mmol/kg Gd-BOPTA 0.1 mmol/kg Gd-DTPA Bueltmann E. Invest Radiol 2008;43:695-702

  10. Study 2: Comparison of Single Dose of Gd-BOPTA and Double Dose of Gd-DTPA • 12 patients with known or suspected stenoocclusive disease of the vessels of interest evaluated with • Gd-DTPA at a dose of 0.2 mmol/kg • Gd-BOPTA at a dose of 0.1 mmol/kg • Increase in SI and CNR [p=0.002] with Gd-BOPTA over Gd-DTPA • Qualitatively superior arterial contrast enhancement & vessel conspicuity with Gd-BOPTA, despite lower dose Pediconi F. Radiol Med2003; 106:87–93

  11. Quantitative Analysis: Contrast-to-Noise Ratios Pediconi F. Radiol Med 2003;106:87-93

  12. Carotid MRA Crossover Comparison 0.2 mmol/kg Gd-DTPA 0.1 mmol/kg Gd-BOPTA Pediconi F. Radiol Med 2003;106:87-93

  13. Summary of Results • In a comparison of equal single doses of Gd-BOPTA and Gd-DTPA, use of Gd-BOPTA resulted in statistically significant improvements in signal intensity (SI) and signal to noise ratio (SNR) • In a comparison of a single dose of Gd-BOPTA with a double dose of Gd-DTPA, Gd-BOPTA resulted in significantly greater increases in SI and SNR than comparator, despite the lower administered dose

  14. Conclusions • Intraindividual CE-MRA studies in the brain and carotid arteries show that MRA may be performed with a single dose of higher-relaxivity Gd-BOPTA • When Gd-BOPTA is administered at the same dose as the non-protein binding comparator Gd-DTPA, enhancement is consistently better • Results are similar when Gd-BOPTA is given at half the dose (0.1 mmol/kg) of the comparator GBCA Gd-DTPA (0.2 mmol/kg) • These results suggest the potential to limit patient exposure to GBCA • Important in era of NSF

  15. References • Broome DR. AJR 2007; 188:586–592 • Sadowski EA. Radiology 2007; 243:148–157 • Pintaske J. Invest Radiol 2006; 41:213-221 • Knopp MV. Invest Radiol 2002; 37:706–715 • Bueltmann E. Invest Radiol 2008; 43:695–702 • Pediconi F. Radiat Med 2003; 106:87–93

More Related